Vanguard Group’s Protalix BioTherapeutics PLX Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $718K | Buy |
+484,798
| New | +$718K | ﹤0.01% | 3839 |
|
|
2024
Q2 | – | Sell |
-330,047
| Closed | -$416K | – | 4435 |
|
|
2024
Q1 | $416K | Buy |
330,047
+27,361
| +9% | +$34.5K | ﹤0.01% | 4059 |
|
|
2023
Q4 | $539K | Buy |
302,686
+21,308
| +8% | +$37.9K | ﹤0.01% | 4006 |
|
|
2023
Q3 | $467K | Buy |
281,378
+51,041
| +22% | +$84.7K | ﹤0.01% | 4067 |
|
|
2023
Q2 | $461K | Buy |
+230,337
| New | +$461K | ﹤0.01% | 4143 |
|
|
2014
Q4 | – | Sell |
-111,956
| Closed | -$271K | – | 4050 |
|
|
2014
Q3 | $271K | Buy |
111,956
+20,248
| +22% | +$49K | ﹤0.01% | 3844 |
|
|
2014
Q2 | $335K | Sell |
91,708
-3,575
| -4% | -$13.1K | ﹤0.01% | 3765 |
|
|
2014
Q1 | $436K | Buy |
95,283
+18,945
| +25% | +$86.7K | ﹤0.01% | 3685 |
|
|
2013
Q4 | $297K | Buy |
76,338
+5,079
| +7% | +$19.8K | ﹤0.01% | 3708 |
|
|
2013
Q3 | $323K | Buy |
71,259
+5,648
| +9% | +$25.6K | ﹤0.01% | 3620 |
|
|
2013
Q2 | $322K | Buy |
+65,611
| New | +$322K | ﹤0.01% | 3569 |
|